GlassScriptPhysician profile
Boris E Rosenfeld
NPI 1518126614
$7,151.35
in general payments reported to CMS, 2019-2025
35 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $884 · 2021: $993 · 2022: $1,170 · 2023: $1,830 · 2024: $901 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,211.69 | 2020-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $604.38 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $507.17 | 2019-2025 | |
| Lilly USA, LLC | $384.19 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $284.96 | 2020-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $236.31 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $203.67 | 2023 | Quviviq |
| Thd America, INC. | $183.06 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $177.97 | 2023-2025 | Dupixent, Evkeeza |
| Glaxosmithkline, LLC. | $133.71 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $125.96 | 2019-2020 | |
| Genzyme Corporation | $117.88 | 2025 | |
| Merck Sharp & Dohme LLC | $98.87 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $86.82 | 2020-2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.33 | 2023-2025 | Caplyta |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Rosenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.